Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project
Liu H et al. Vaccine (2016). http://dx.doi.org/10.1016/j.vaccine.2016.10.040

Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population
Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, Bruzil S, Haima KY, Gottlieb T, Ben-Yedidia T
Vaccine. 2014 Oct 7;32(44):5816-23

Epitope-Based Approached to a Universal Influenza Vaccine
Gottlieb T and Ben-Yedidia T
J.Autoimmun, 54:15-20, 2014 

Safety and Immunogenicity of Multimeric-001 – a Novel Universal Influenza Vaccine
Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T.
Journal of Clinical Immunology, 32(3):595-603, 2012

Development of a Universal Influenza Vaccine
Rudolph W, Ben-Yedidia T.
BioProcess International, Vol. 9, No. S8, September 2011, pp. 46–49.

Progress towards a universal influenza vaccine
Ben-Yedidia T.
Future Virology, February 2011, Vol. 6, No. 2, Pages 237-248.

A universal influenza vaccine: Where are we in the pursuit of this “Holy Grail”?
Rudolph W, Ben-Yedidia T.
Hum Vaccin. 2011 Jan; 7(1):10-11.

The 3rd International Conference on Influenza Vaccines for the World (IVW 2009)
Ben-Yedidia T.
Hum Vaccin. 2009 Aug;5(8):508-9. Epub 2009 Aug 27.

A universal epitope-based influenza vaccine and its efficacy against H5N1
Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, Ben-Yedidia T.
Vaccine 27 (2009) 2099–2107.

Epitope-based vaccine against influenza
Ben-Yedidia T, Arnon R.
Expert Rev Vaccines. 2007 Dec;6(6):939-48. Review.

Flagella as a platform for epitope-based vaccines
Ben-Yedidia T, Arnon R.
Isr Med Assoc J. 2006 May;8(5):316-8.

Towards an epitope-based human vaccine for influenza
Ben-Yedidia T, Arnon R.
Hum Vaccin. 2005 May-Jun;1(3):95-101. Epub 2005 May 15.

A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin
Jeon SH, Kayhan B, Ben-Yedidia T, Arnon R.
J Biol Chem. 2004 Nov 12;279(46):48410-9. Epub 2004 Sep 8.

Old and new vaccine approaches
Arnon R, Ben-Yedidia T.
Int Immunopharmacol. 2003 Aug; 3(8):1195-204.

A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization
Ben-Yedidia T, Beignon AS, Partidos CD, Muller S, Arnon R.
Mol Immunol. 2002 Oct;39(5-6):323-31.

Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus
Jeon SH, Ben-Yedidia T, Arnon R.
Vaccine. 2002 Jun 21;20(21-22):2772-80.

Peptide-based synthetic recombinant vaccines with anti-viral efficacy
Arnon R, Tarrab-Hazdai R, Ben-Yedidia T.
Biologicals. 2001 Sep-Dec;29(3-4):237-42.

Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni
Ben-Yedidia T, Tarrab-Hazdai R, Schechtman D, Arnon R.
Infect Immun. 1999 Sep;67(9):4360-6.

Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection
Ben-Yedidia T, Marcus H, Reisner Y, Arnon R.
Int Immunol. 1999 Jul;11(7):1043-51.

Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine
Ben-Yedidia T, Arnon R.
Immunol Lett. 1998 Nov;64(1):9-15.

Efficacy of anti-influenza peptide vaccine in aged mice
Ben-Yedidia T, Abel L, Arnon R, Globerson A.
Mech Ageing Dev. 1998 Aug 1;104(1):11-23.

Design of peptide and polypeptide vaccines
Ben-Yedidia T, Arnon R.
Curr Opin Biotechnol. 1997 Aug;8(4):442-8.

Synthetic recombinant vaccine induces anti-influenza long-term immunity and cross-strain protection
Arnon R, Levi R.
Adv Exp Med Biol. 1996;397:23-9.